These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

903 related articles for article (PubMed ID: 19720919)

  • 41. Morphologic characterization of acute myeloid leukemia with cytogenetic or molecular evidence of t(8;21), t(15;17), inv(16) and 11q23 abnormalities.
    Rozman M; Navarro JT; Domingo A; Ayats R; Vallespí T; Gallart M; Florensa L;
    Haematologica; 2002 Aug; 87(8):886-7. PubMed ID: 12161368
    [No Abstract]   [Full Text] [Related]  

  • 42. M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience.
    Pulsoni A; Iacobelli S; Bernardi M; Borgia M; Camera A; Cantore N; Di Raimondo F; Fazi P; Ferrara F; Leoni F; Liso V; Mancini M; Marmont F; Matturro A; Maurillo L; Melillo L; Meloni G; Mirto S; Specchia G; Valentini CG; Venditti A; Leone G; Foà R; Mandelli F; Pagano L
    Haematologica; 2008 Jul; 93(7):1025-32. PubMed ID: 18508801
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
    Duployez N; Marceau-Renaut A; Boissel N; Petit A; Bucci M; Geffroy S; Lapillonne H; Renneville A; Ragu C; Figeac M; Celli-Lebras K; Lacombe C; Micol JB; Abdel-Wahab O; Cornillet P; Ifrah N; Dombret H; Leverger G; Jourdan E; Preudhomme C
    Blood; 2016 May; 127(20):2451-9. PubMed ID: 26980726
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Retrospective analysis of treatment outcomes in 70 patients with t(8;21) acute myeloid leukemia].
    Numata A; Fujimaki K; Aoshima T; Onizuka M; Hagihara M; Miyazaki K; Fujita H; Sakai R; Machida S; Tanaka E; Nakajima Y; Hattori Y; Tanaka M; Yamazaki E; Shirasugi Y; Inoue Y; Watanabe S; Fujisawa S
    Rinsho Ketsueki; 2012 Jul; 53(7):698-704. PubMed ID: 22975772
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients.
    de Bont ES; Fidler V; Meeuwsen T; Scherpen F; Hählen K; Kamps WA
    Clin Cancer Res; 2002 Sep; 8(9):2856-61. PubMed ID: 12231527
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
    Marcucci G; Stock W; Dai G; Klisovic RB; Liu S; Klisovic MI; Blum W; Kefauver C; Sher DA; Green M; Moran M; Maharry K; Novick S; Bloomfield CD; Zwiebel JA; Larson RA; Grever MR; Chan KK; Byrd JC
    J Clin Oncol; 2005 May; 23(15):3404-11. PubMed ID: 15824414
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission.
    Ferrara F; Morabito F; Latagliata R; Martino B; Annunziata M; Oliva E; Schiavone EM; Pollio F; Palmieri S; Gianfaldoni G; Leoni F
    Haematologica; 2001 Aug; 86(8):814-20. PubMed ID: 11522537
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Standard induction chemotherapy followed by attenuated consolidation in elderly patients with acute myeloid leukemia.
    Lee JH; Choi SJ; Lee JH; Park JH; Kim H; Joo YD; Lee WS; Zang DY; Kim HJ; Lee KH;
    Ann Hematol; 2006 Jun; 85(6):357-65. PubMed ID: 16575580
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia.
    Etienne A; Esterni B; Charbonnier A; Mozziconacci MJ; Arnoulet C; Coso D; Puig B; Gastaut JA; Maraninchi D; Vey N
    Cancer; 2007 Apr; 109(7):1376-83. PubMed ID: 17326052
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
    Clavio M; Venturino C; Pierri I; Garrone A; Miglino M; Canepa L; Balleari E; Balocco M; Michelis GL; Ballerini F; Gobbi M
    Ann Hematol; 2004 Nov; 83(11):696-703. PubMed ID: 15322763
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia.
    Lashkari A; Lowe T; Collisson E; Paquette R; Emmanouilides C; Territo M; Schiller G
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):466-71. PubMed ID: 16545730
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Characteristic clinical features and treatment of acute myelocytic leukemia with 8;21 translocation].
    Kyo T
    Rinsho Ketsueki; 1994 Mar; 35(3):245-9. PubMed ID: 8158843
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.
    Rizzieri DA; O'Brien JA; Broadwater G; Decastro CM; Dev P; Diehl L; Beaven A; Lagoo A; Gockerman JP; Chao NJ; Moore JO
    Cancer; 2009 Jul; 115(13):2922-9. PubMed ID: 19452542
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
    Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Good outcome of children with acute myeloid leukemia and t(8;21)(q22;q22), even when associated with granulocytic sarcoma: a report from a single institution in Argentina.
    Felice MS; Zubizarreta PA; Alfaro EM; Gallego MS; Cygler AM; Rosso DA; Rossi JG; Sackmann-Muriel F
    Cancer; 2000 Apr; 88(8):1939-44. PubMed ID: 10760772
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Retrospective study of acute myelogenous leukemia in elderly patients: treatment and outcome of 83 consecutive patients].
    Ino T; Tsuzuki M; Hasegawa A; Miyazaki H; Kojima H; Maruyama F; Okamoto M; Matsui T; Ezaki K; Hirano M
    Rinsho Ketsueki; 2000 Apr; 41(4):303-9. PubMed ID: 10846460
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
    Tsukimoto I; Tawa A; Horibe K; Tabuchi K; Kigasawa H; Tsuchida M; Yabe H; Nakayama H; Kudo K; Kobayashi R; Hamamoto K; Imaizumi M; Morimoto A; Tsuchiya S; Hanada R
    J Clin Oncol; 2009 Aug; 27(24):4007-13. PubMed ID: 19620491
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acute myeloid leukemia with inv(16)(p13q22): involvement of cervical lymph nodes and tonsils is common and may be a negative prognostic sign.
    Billström R; Ahlgren T; Békássy AN; Malm C; Olofsson T; Höglund M; Mitelman F; Johansson B
    Am J Hematol; 2002 Sep; 71(1):15-9. PubMed ID: 12221668
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].
    Shao B; Gao YR; Wang C; Yan SK; Cai Q; Jiang JL; Yang J; Bai HT; Zhao M; Zhao CX
    Ai Zheng; 2006 Aug; 25(8):1007-12. PubMed ID: 16965684
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?
    Dombret H; Preudhomme C; Boissel N
    Curr Opin Hematol; 2009 Mar; 16(2):92-7. PubMed ID: 19468270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.